Cue Biopharma, Inc. (CUE) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cue Biopharma (CUE) PT Lowered to $4 at Jefferies
November 15, 2024 8:59 AM ESTJefferies analyst Maury Raycroft lowered the price target on Cue Biopharma (NASDAQ: CUE) to $4.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Stock has surged ~230% following CUE's recent $12M capital raise. However, the cash overhang still remains ($32M), limiting cos ability to... More
